An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa

Journal of the American Academy of Dermatology

Volumn 70, Issue 2, 2014, Pages 243-251

  Leslie, Kieron S ^a   Tripathi, Shivani V ^a   Nguyen, Tien V ^a   Pauli, Mariela ^a   Rosenblum, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anakinra; hidradenitis suppurativa; inflammation; interleukin 1; T cells; treatment

Indexed keywords

RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTICLE; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; DERMATOLOGY LIFE QUALITY INDEX; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; LYMPHOCYTE COUNT; PRIORITY JOURNAL; SKIN DEFECT; SUPPURATIVE HIDRADENITIS; T LYMPHOCYTE; TREATMENT DURATION; ADULT; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HIDRADENITIS SUPPURATIVA; MALE; PATIENT SATISFACTION; PILOT STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIDRADENITIS SUPPURATIVA; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; PATIENT SATISFACTION; PILOT PROJECTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84892672645     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.09.044     Document Type: Article

References (36)

1. A.J. Onderdijk, H.H. van der Zee, S. Esmann, S. Lophaven, D.N. Dufour, and G.B. Jemec et al. Depression in patients with hidradenitis suppurativa J Eur Acad Dermatol Venereol 27 2013 473 478
2. I. Cosmatos, A. Matcho, R. Weinstein, M.O. Montgomery, and P. Stang Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States J Am Acad Dermatol 68 2013 412 419
3. G.B. Jemec, M. Heidenheim, and N.H. Nielsen The prevalence of hidradenitis suppurativa and its potential precursor lesions J Am Acad Dermatol 35 1996 191 194
4. H.H. van der Zee, L. de Ruiter, D.G. van den Broecke, W.A. Dik, J.D. Laman, and E.P. Prens et al. Elevated levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β Br J Dermatol 164 2011 1292 1298
5. C. Schlapbach, T. Hänni, N. Yawalkar, and R.E. Hunger et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa J Am Acad Dermatol 65 2011 790 798
6. A. Grant, T. Gonzalez, M.O. Montgomery, V. Cardenas, and F.A. Kerdel Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial J Am Acad Dermatol 62 2010 205 217
7. C. Cusack, and C. Buckley Etanercept: effective in the management of hidradenitis suppurativa Br J Dermatol 154 2006 726 729
8. E.J. Giamarellos-Bourboulis, E. Pelekanou, A. Antonopoulou, H. Petropoulou, F. Baziaka, and V. Karagianni et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa Br J Dermatol 158 2008 567 572
9. D.R. Adams, J.A. Yankura, A.C. Fogelberg, and B.E. Anderson Treatment of hidradenitis suppurativa with etanercept injection Arch Dermatol 146 2010 501 504
10. R.A. Lee, E. Dommasch, J. Treat, J. Sciacca-Kirby, J. Chachkin, and S. Williams A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa J Am Acad Dermatol 60 2009 565 573
11. A.B. Kimball, F. Kerdel, D. Adams, U. Mrowietz, J.M. Gelfand, and R. Gniadecki et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial Ann Intern Med 157 2012 846 855
12. W.P. Gulliver, G.B.E. Jemec, and K.A. Baker Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa J Eur Acad Dermatol Venereol 26 2012 911 914
13. V.R. Sharon, M.S. Garcia, S. Bagheri, H. Goodarzi, C. Yang, and Y. Ono et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab Acta Derm Venereol 92 2012 320 321
14. E.M. Baerveldt, J.H. Kappen, H.B. Thio, J.A. van Laar, P.M. van Hagen, and L.P. Prens Successful long-term triple disease control by ustekinumab in a patient with Behçet's disease, psoriasis and hidradenitis suppurativa Ann Rheum Dis 72 2013 626 627
15. J.L. Hsiao, R.J. Antaya, T. Berger, T. Maurer, K. Shinkai, and K.S. Leslie Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review Arch Dermatol 146 2010 1265 1270
16. S. Stojanov, and D.L. Kastner Familial autoinflammatory diseases: genetics, pathogenesis and treatment Curr Opin Rheumatol 17 2005 586 599
17. K.S. Leslie, H.J. Lachmann, E. Bruning, J.A. McGrath, A. Bybee, and J.R. Gallimore et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations Arch Dermatol 142 2006 1591 1597
18. L. Obici, A. Meini, M. Cattalini, S. Chicca, M. Galliani, and S. Donadei et al. Favorable and sustained response to anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis Ann Rheum Dis 70 2011 1511 1512
19. K. Stankovic Stojanovic, Y. Delmas, P.U. Torres, J. Peltier, G. Pelle, and I. Jéru et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure Nephrol Dial Transplant 27 2012 1898 1901
20. K. Sartorius, L. Emtestam, G.B.E. Jemec, and J. Lapins Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity Br J Dermatol 161 2009 831 839
21. H.H. Van der Zee, and E.P. Prens Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report Dermatology 226 2013 97 100
22. H.S. Smith, J.D. Chao, and J. Teitelbaum Painful hidradenitis suppurativa Clin J Pain 26 2010 435 444
23. S. Esmann, and G.B.E. Jemec Psychosocial impact of hidradenitis suppurativa: a qualitative study Acta Derm Venereol 91 2011 328 332
24. A. Kurek, E.M. Peters, A. Chanwangpong, R. Sabat, W. Sterry, and S. Schneider-Burrus Profound disturbances of sexual health in patients with acne inversa J Am Acad Dermatol 67 2012 422 428.e1
25. R. Shikiar, M.K. Willian, M.M. Okun, C.S. Thompson, and D.A. Revicki The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study Health Qual Life Outcomes 4 2006 71
26. I. Miller, C.D. Lynggaard, S. Lophaven, C. Zachariae, D.N. Dufour, and GB. Jemec A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa Br J Dermatol 165 2011 391 398
27. M. Amano, A. Grant, and F.A. Kerdel A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa Int J Dermatol 49 2010 950 955
28. J.R. Mekkes, and J.D. Bos Long-term efficacy of a single course of infliximab in hidradenitis suppurativa Br J Dermatol 158 2008 370 374
29. H. Belani, L. Gensler, U. Bajpai, E. Meinhardt, J. Graf, and L. Pincus et al. Neutrophilic urticaria with systemic inflammation: a case series JAMA Dermatol 149 2013 453 458
30. R.M. Fleischmann, J. Schechtman, R. Bennett, M.L. Handel, G.R. Burmester, and J. Tesser et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial Arthritis Rheum 48 2003 927 934
31. M.A. Lopez-Olivo, J.H. Tayar, J.A. Martinez-Lopez, E.N. Pollono, J.P. Cueto, and M.R. Gonzales-Crespo et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis JAMA 308 2012 898 908
32. J.E. Sims, and D.E. Smith The IL-1 family: regulators of immunity Nat Rev Immunol 10 2010 89 102
33. J.E. Sims, C.J. March, D. Cosman, M.B. Widmer, H.R. MacDonald, and C.J. McMahan et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily Science 241 1988 585 589
34. S.Z. Ben-Sasson, S. Caucheteux, M. Crank, J. Hu-Li, and W.E. Paul IL-1 acts on T cells to enhance the magnitude of in vivo immune responses Cytokine 56 2011 122 125
35. A. Weber, P. Wasiliew, and M. Kracht Interleukin-1 (IL-1) pathway Sci Signal 3 2010 cm1
36. S. Vallabhapurapu, and M. Karin Regulation and function of NF-kappaB transcription factors in the immune system Annu Rev Immunol 27 2009 693 733